This stock is on an overshooting uptrend. Next levels are 1.29$, 2.15$ and 2.75$. The company has a joint venture with Merck and several release candidates passing Phase II.
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.